FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:921 September 16, 1999 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In their placebo-controlled study, Lowance et al. (May 13 issue)¹ found that treatment with valacyclovir markedly reduced the incidence of cytomegalovirus (CMV) disease after renal transplantation. The reduction in CMV disease among CMV-seronegative recipients was accompanied by a 50 percent reduction in the rate of acute graft rejection. Of concern, however, is the fact that this study was performed with a placebo control. The authors state that this approach was acceptable because "there was no accepted standard regimen of prophylaxis at the inception of the study." At the time the study began — July 7, 1992 — . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.